Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
667.20B
Market cap667.20B
Price-Earnings ratio
28.97
Price-Earnings ratio28.97
Dividend yield
2.10%
Dividend yield2.10%
Average volume
8.53M
Average volume8.53M
High today
$271.30
High today$271.30
Low today
$261.35
Low today$261.35
Open price
$262.90
Open price$262.90
Volume
9.64M
Volume9.64M
52 Week high
$271.30
52 Week high$271.30
52 Week low
$164.23
52 Week low$164.23

Stock Snapshot

With a market cap of 667.2B, Johnson & Johnson(JNJ) trades at $270.89. The stock has a price-to-earnings ratio of 28.97 and currently yields dividends of 2.10%.

As of 2026-07-27, Johnson & Johnson(JNJ) stock has fluctuated between $261.35 and $271.30. The current price stands at $270.89, placing the stock +3.7% above today's low and -0.2% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 9.64M, compared to an average daily volume of 8.53M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $271.30 and a 52-week low of $164.23.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $271.30 and a 52-week low of $164.23.

JNJ News

TipRanks 7m
J&J announces proposed resolution of ovarian talc litigation

Johnson & Johnson announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading th...

TipRanks 7m
J&J to settle ovarian talc claims for $5.5B

18:34 EDT J&J to settle ovarian talc claims for $5.5B Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try...

TipRanks 7m
J&J proposes to pay up to $3B in first talc installment in 2027

18:35 EDT J&J proposes to pay up to $3B in first talc installment in 2027 Unlock powerful investing tools with TipRanks Premium to make smarter, more confident...

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
23.1%
Sell
3.8%

More JNJ News

BBC 5h
JJ McKiernan: Bromley sign midfielder from Lincoln City - BBC

...

JJ McKiernan: Bromley sign midfielder from Lincoln City - BBC
TipRanks 6h
After industry event, Piper sees Intuitive Surgical as dominant player

After attending the Society of Robotic Surgery meeting, Piper Sandler sees “lots of greenfield ahead” for the soft tissue robotic category. While robot-assisted...

Nasdaq 7h
J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech s...

J&J's MedTech Performance Slows in Q2: Will Sales Improve in H2?
24/7 Wall St. 7h
Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck

Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck By Joel South Published Jul 27, 11:40AM EDT Quick Read Realt...

Forget Social Security: 5 Sleep-at-Night Dividend Stocks Retirees Are Using to Replace a Paycheck
24/7 Wall St. 1d
How to Build $4,000 a Month in Dividend Income Without Selling a Single Share

How to Build $4,000 a Month in Dividend Income Without Selling a Single Share By Michael Williams Published Jul 26, 12:51PM EDT Quick Read Generating $48,000...

How to Build $4,000 a Month in Dividend Income Without Selling a Single Share
Nasdaq 2d
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?

Key Points These two companies are pharmaceutical giants. Both seem somewhat overvalued at recent levels. Still, they're likely to do well over the long term...

Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
Simply Wall St 2d
Should J&J’s Oncology and MedTech Breakthroughs Prompt a Fresh Look From Johnson & Johnson Investors?

Johnson & Johnson recently reported strong second-quarter 2026 results, lifted its full-year sales outlook to US$100.80 billion–US$101.40 billion, and announced...

Should J&J’s Oncology and MedTech Breakthroughs Prompt a Fresh Look From Johnson & Johnson Investors?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.